Menu
Search
|

Menu

Close
X

Calithera Biosciences Inc CALA.OQ (NASDAQ Stock Exchange Global Select Market)

8.10 USD
+1.15 (+16.55%)
As of Feb 16
chart
Previous Close 6.95
Open 7.50
Volume 502,018
3m Avg Volume 139,234
Today’s High 8.65
Today’s Low 7.50
52 Week High 20.00
52 Week Low 6.57
Shares Outstanding (mil) 35.48
Market Capitalization (mil) 287.36
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
19
FY16
0
FY15
0
EPS (USD)
FY17
-0.539
FY16
-1.957
FY15
-1.809
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.43
Price to Sales (TTM)
vs sector
15.37
8.57
Price to Book (MRQ)
vs sector
1.82
5.14
Price to Cash Flow (TTM)
vs sector
--
25.75
Total Debt to Equity (MRQ)
vs sector
0.00
15.12
LT Debt to Equity (MRQ)
vs sector
0.00
11.85
Return on Investment (TTM)
vs sector
-23.73
13.54
Return on Equity (TTM)
vs sector
-24.89
14.80

EXECUTIVE LEADERSHIP

Susan Molineaux
President, Chief Executive Officer, Co-Founder, Director, Since 2010
Salary: $475,000.00
Bonus: $237,500.00
Curtis Hecht
Senior Vice President - Business and Corporate Development, Since 2016
Salary: --
Bonus: --
Christopher Molineaux
Senior Vice President - Development, Since 2013
Salary: $300,000.00
Bonus: $105,000.00
Keith Orford
Senior Vice President, Clinical Development, Since 2015
Salary: $333,667.00
Bonus: $111,443.00
Eric Sjogren
Senior Vice President - Drug Discovery, Since 2010
Salary: $300,000.00
Bonus: $105,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

343 Oyster Point Blvd # 200
SOUTH SAN FRANCISCO   CA   94080-1913

Phone: +1650.8701000

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

SPONSORED STORIES